289 related articles for article (PubMed ID: 26324762)
21. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
22. Evidence for an oncogenic modifier role for mutant histone acetyltransferases in diffuse large B-cell lymphoma.
Haery L; Mussakhan S; Waxman DJ; Gilmore TD
Leuk Lymphoma; 2016 Nov; 57(11):2661-71. PubMed ID: 27003102
[TBL] [Abstract][Full Text] [Related]
23. The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL).
Bavi P; Uddin S; Bu R; Ahmed M; Abubaker J; Balde V; Qadri Z; Ajarim D; Al-Dayel F; Hussain AR; Al-Kuraya KS
J Pathol; 2011 Jul; 224(3):355-66. PubMed ID: 21506127
[TBL] [Abstract][Full Text] [Related]
24. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
[TBL] [Abstract][Full Text] [Related]
25. Role of nuclear factor-κB regulators TNFAIP3 and CARD11 in Middle Eastern diffuse large B-cell lymphoma.
Bu R; Bavi P; Abubaker J; Jehan Z; Al-Haqawi W; Ajarim D; Al-Dayel F; Uddin S; Al-Kuraya KS
Leuk Lymphoma; 2012 Oct; 53(10):1971-7. PubMed ID: 22397314
[TBL] [Abstract][Full Text] [Related]
26. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.
Shen R; Fu D; Dong L; Zhang MC; Shi Q; Shi ZY; Cheng S; Wang L; Xu PP; Zhao WL
Signal Transduct Target Ther; 2023 Apr; 8(1):145. PubMed ID: 37032379
[TBL] [Abstract][Full Text] [Related]
27. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes.
Feuerhake F; Kutok JL; Monti S; Chen W; LaCasce AS; Cattoretti G; Kurtin P; Pinkus GS; de Leval L; Harris NL; Savage KJ; Neuberg D; Habermann TM; Dalla-Favera R; Golub TR; Aster JC; Shipp MA
Blood; 2005 Aug; 106(4):1392-9. PubMed ID: 15870177
[TBL] [Abstract][Full Text] [Related]
28. The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma.
Eluard B; Nuan-Aliman S; Faumont N; Collares D; Bordereaux D; Montagne A; Martins I; Cagnard N; Caly M; Taoui O; Lordello L; Lehmann-Che J; Tesson B; Martinez-Climent JA; Copie-Bergman C; Haioun C; Tilly H; Bonsang B; Vincent-Salomon A; Jais JP; Jardin F; Leroy K; Maiuri MC; Kroemer G; Molina TJ; Feuillard J; Baud V
Blood; 2022 Jan; 139(3):384-398. PubMed ID: 34232979
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile.
Chin M; Herscovitch M; Zhang N; Waxman DJ; Gilmore TD
Oncogene; 2009 May; 28(20):2100-11. PubMed ID: 19377508
[TBL] [Abstract][Full Text] [Related]
30. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.
Savage KJ; Monti S; Kutok JL; Cattoretti G; Neuberg D; De Leval L; Kurtin P; Dal Cin P; Ladd C; Feuerhake F; Aguiar RC; Li S; Salles G; Berger F; Jing W; Pinkus GS; Habermann T; Dalla-Favera R; Harris NL; Aster JC; Golub TR; Shipp MA
Blood; 2003 Dec; 102(12):3871-9. PubMed ID: 12933571
[TBL] [Abstract][Full Text] [Related]
31. [Significance of miR-155, miR-34a and miR-30a expression in diffuse large B-cell lymphoma].
Sun GX; Cao XS; Li Q; Wang Z; Peng J; Lu CQ
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Feb; 30(1):79-83. PubMed ID: 23450486
[TBL] [Abstract][Full Text] [Related]
32. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological implications of nuclear factor κB signal pathway activation in diffuse large B-cell lymphoma.
Zhao Q; Fu W; Jiang H; Du J; Zhang C; Xi H; Zhou F; Li R; Hou J
Hum Pathol; 2015 Apr; 46(4):524-31. PubMed ID: 25636172
[TBL] [Abstract][Full Text] [Related]
34. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.
Compagno M; Lim WK; Grunn A; Nandula SV; Brahmachary M; Shen Q; Bertoni F; Ponzoni M; Scandurra M; Califano A; Bhagat G; Chadburn A; Dalla-Favera R; Pasqualucci L
Nature; 2009 Jun; 459(7247):717-21. PubMed ID: 19412164
[TBL] [Abstract][Full Text] [Related]
35. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
Xu-Monette ZY; Møller MB; Tzankov A; Montes-Moreno S; Hu W; Manyam GC; Kristensen L; Fan L; Visco C; Dybkaer K; Chiu A; Tam W; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Wu L; Zhao X; Bueso-Ramos CE; Wang SA; Go RS; Li Y; Winter JN; Piris MA; Medeiros LJ; Young KH
Blood; 2013 Oct; 122(15):2630-40. PubMed ID: 23982177
[TBL] [Abstract][Full Text] [Related]
36. [Mechanism and clinical significance of anti-apoptotic gene bcl-2 expression in diffuse large B-cell lymphoma].
Zeng LP; Wen YL; Ma Y; Wang GQ; Li Y; Wang J; Xu LL; Zhang XM
Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):377-81. PubMed ID: 21914345
[TBL] [Abstract][Full Text] [Related]
37. Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways.
Pham LV; Fu L; Tamayo AT; Bueso-Ramos C; Drakos E; Vega F; Medeiros LJ; Ford RJ
Blood; 2011 Jan; 117(1):200-10. PubMed ID: 20889926
[TBL] [Abstract][Full Text] [Related]
38. Prognostic impact of C-REL expression in diffuse large B-cell lymphoma.
Curry CV; Ewton AA; Olsen RJ; Logan BR; Preti HA; Liu YC; Perkins SL; Chang CC
J Hematop; 2009 Mar; 2(1):20-6. PubMed ID: 19669219
[TBL] [Abstract][Full Text] [Related]
39. Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.
Bognar MK; Vincendeau M; Erdmann T; Seeholzer T; Grau M; Linnemann JR; Ruland J; Scheel CH; Lenz P; Ott G; Lenz G; Hauck SM; Krappmann D
Oncogene; 2016 Aug; 35(32):4269-81. PubMed ID: 26776161
[TBL] [Abstract][Full Text] [Related]
40. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.
Davis RE; Brown KD; Siebenlist U; Staudt LM
J Exp Med; 2001 Dec; 194(12):1861-74. PubMed ID: 11748286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
